KEY POINTS
  • A third dose of the vaccine elicited a strong immune response and was well tolerated by the kids with a majority of the side effects mild to moderate, according to Pfizer.
  • Parents have been waiting months for the FDA to authorize the shots for kids under age 5.
  • The FDA announced its committee of independent experts will on June 15 review Pfizer's and Moderna's applications to authorize their vaccines for infants through preschoolers.
  • During the massive wave of omicron infection during the winter, children younger than age 5 were hospitalized with Covid at five times the rate of the pandemic peak, according to the Centers for Disease Control and Prevention.

In this article

A healthcare worker administers a Pfizer-BioNTech Covid-19 vaccine to a child at vaccination site in San Francisco, California, U.S., on Monday, Jan. 10, 2022.

Pfizer and BioNTech's three-dose Covid vaccine for children 6 months to 5 years old was 80% effective at preventing illness during the omicron wave, according to preliminary clinical trial results released Monday.

A third dose of the vaccine elicited a strong immune response and was well tolerated by the kids with a majority of the side effects mild to moderate, according to the companies.

In this article